| Chapter Number |
Article ID |
Article Title |
Article URL |
Author(s) Name |
TTS Conversion |
Total Number of Views |
| 1 |
1.1.1 |
Discovery of Nitric Oxide and its Role in Vascular Biology |
https://pharmaceuticalintelligence.com/2012/09/18/discovery-of-nitric-oxide-and-its-role-in-vascular-biology/ |
Aviral Vatsa PhD, MBBS |
✓
|
535 |
| 1 |
1.1.2 |
Nitric Oxide: The Nobel Prize in Physiology or Medicine 1998 Robert F. Furchgott, Louis J. Ignarro, Ferid Murad |
https://pharmaceuticalintelligence.com/2012/08/16/nitric-oxide-the-nobel-prize-in-physiology-or-medicine-1998-robert-f-furchgott-louis-j-ignarro-ferid-murad/ |
Aviva Lev-Ari, PhD, RN |
✓
|
436 |
| 1 |
1.2.1 |
Nitric Oxide: a short historic perspective |
https://pharmaceuticalintelligence.com/2012/08/05/nitric-oxide-a-short-historic-perspective-7/ |
Aviral Vatsa PhD, MBBS |
✓
|
176 |
| 1 |
1.2.2 |
Nitric Oxide: role in Cardiovascular health and disease |
https://pharmaceuticalintelligence.com/2012/09/11/nitric-oxide-role-in-cardiovascular-health-and-disease/ |
Aviral Vatsa PhD, MBBS |
✓
|
691 |
| 1 |
1.3.1 |
Nitric Oxide: Chemistry and function |
https://pharmaceuticalintelligence.com/2012/08/10/nitric-oxide-chemistry-and-function/ |
Aviral Vatsa PhD, MBBS |
✓
|
364 |
| 1 |
1.4.1 |
Nitric Oxide Signalling Pathways |
https://pharmaceuticalintelligence.com/2012/08/22/nitric-oxide-signalling-pathways/ |
Aviral Vatsa PhD, MBBS |
✓
|
306 |
| 1 |
1.4.2 |
Nitric Oxide has a Ubiquitous Role in the Regulation of Glycolysis – with a Concomitant Influence on Mitochondrial Function |
https://pharmaceuticalintelligence.com/2012/09/16/nitric-oxide-has-a-ubiquitous-role-in-the-regulation-of-glycolysis-with-a-concomitant-influence-on-mitochondrial-function/ |
Larry H. Bernstein, MD, FACP, Clinical Pathologist and Biochemist |
✓
|
1377 |
| 1 |
1.5.1 |
Mitochondrial Damage and Repair under Oxidative Stress |
https://pharmaceuticalintelligence.com/2012/10/28/mitochondrial-damage-and-repair-under-oxidative-stress/ |
Larry H. Bernstein, MD, FACP, Clinical Pathologist and Biochemist |
✓
|
1655 |
| 1 |
1.6.1 |
Interaction of Nitric Oxide and Prostacyclin in Vascular Endothelium |
https://pharmaceuticalintelligence.com/2012/09/14/interaction-of-nitric-oxide-and-prostacyclin-in-vascular-endothelium/ |
Larry H. Bernstein, MD, FACP, Clinical Pathologist and Biochemist |
✓
|
562 |
| 1 |
1.6.2 |
Prostacyclin and Nitric Oxide: Adventures in Vascular Biology – A Tale of Two Mediators |
https://pharmaceuticalintelligence.com/2013/04/30/prostacyclin-and-nitric-oxide-adventures-in-vascular-biology-a-tale-of-two-mediators/ |
Aviva Lev-Ari, PhD, RN |
✓
|
118 |
| 2 |
2.1.1 |
Blood-vessels-generating stem cells discovered |
https://pharmaceuticalintelligence.com/2012/10/22/blood-vessel-generating-stem-cells-discovered/ |
Ritu Saxena, Ph.D. |
✓
|
238 |
| 2 |
2.1.2 |
Differential Distribution of Nitric Oxide – A 3-D Mathematical Model |
https://pharmaceuticalintelligence.com/2012/10/28/differential-distribution-of-nitric-oxide-a-3-d-mathematical-model/ |
Anamika Sarkar, Ph.D. |
✓
|
314 |
| 2 |
2.1.3 |
NO Nutritional remedies for hypertension and atherosclerosis. It’s 12 am: do you know where your electrons are? |
https://pharmaceuticalintelligence.com/2012/10/07/no-nutritional-remedies-for-hypertension-and-atherosclerosis-its-12-am-do-you-know-where-your-electrons-are/ |
Meg Baker, Ph.D., Registered Patent Agent |
✓
|
689 |
| 2 |
2.2.1 |
Statins’ Nonlipid Effects on Vascular Endothelium through eNOS Activation |
https://pharmaceuticalintelligence.com/2012/10/08/statins-nonlipid-effects-on-vascular-endothelium-through-enos-activation/ |
Larry Bernstein, MD, FACP |
✓
|
879 |
| 2 |
2.2.2 |
Endothelial Function and Cardiovascular Disease |
https://pharmaceuticalintelligence.com/2012/10/25/endothelial-function-and-cardiovascular-disease/ |
Larry Bernstein, MD, FACP |
✓
|
561 |
| 2 |
2.2.3 |
Endothelin Receptors in Cardiovascular Diseases: The Role of eNOS Stimulation |
https://pharmaceuticalintelligence.com/2012/10/04/endothelin-receptors-in-cardiovascular-diseases-the-role-of-enos-stimulation/ |
Aviva Lev-Ari, PhD, RN |
✓
|
273 |
| 3 |
3.1.1 |
Cardiovascular Disease (CVD) and the Role of Agent Alternatives in endothelial Nitric Oxide Synthase (eNOS) Activation and Nitric Oxide Production |
https://pharmaceuticalintelligence.com/2012/07/19/cardiovascular-disease-cvd-and-the-role-of-agent-alternatives-in-endothelial-nitric-oxide-synthase-enos-activation-and-nitric-oxide-production/ |
Aviva Lev-Ari, PhD, RN |
✓
|
365 |
| 3 |
3.1.2 |
Telling NO to Cardiac Risk |
https://pharmaceuticalintelligence.com/2012/12/10/telling-no-to-cardiac-risk/ |
Stephen J. Williams, PhD |
✓
|
538 |
| 3 |
3.1.3 |
Nitric Oxide and it’s impact on Cardiothoracic Surgery |
https://pharmaceuticalintelligence.com/2012/12/15/nitric-oxide-and-its-impact-on-cardiothoracic-surgery/ |
Tilda Barliya PhD |
✓
|
1760 |
| 3 |
3.2.1 |
Inhibition of ET-1, ETA and ETA-ETB, Induction of NO production, stimulation of eNOS and Treatment Regime with PPAR-gamma agonists (TZD): cEPCs Endogenous Augmentation for Cardiovascular Risk Reduction – A Bibliography |
https://pharmaceuticalintelligence.com/2012/10/04/inhibition-of-et-1-eta-and-eta-etb-induction-of-no-production-and-stimulation-of-enos-and-treatment-regime-with-ppar-gamma-agonists-tzd-cepcs-endogenous-augmentation-for-cardiovascular-risk-reduc/ |
Aviva Lev-Ari, PhD, RN |
✓
|
165 |
| 3 |
3.2.2 |
Bystolic’s generic Nebivolol – Positive Effect on circulating Endothelial Progenitor Cells Endogenous Augmentation |
https://pharmaceuticalintelligence.com/2012/07/16/bystolics-generic-nebivolol-positive-effect-on-circulating-endothilial-progrnetor-cells-endogenous-augmentation/ |
Aviva Lev-Ari, PhD, RN |
✓
|
1472 |
| 3 |
3.2.3 |
Positioning a Therapeutic Concept for Endogenous Augmentation of cEPCs — Therapeutic Indications for Macrovascular Disease: Coronary, Cerebrovascular and Peripheral |
https://pharmaceuticalintelligence.com/2012/08/29/positioning-a-therapeutic-concept-for-endogenous-augmentation-of-cepcs-therapeutic-indications-for-macrovascular-disease-coronary-cerebrovascular-and-peripheral/ |
Aviva Lev-Ari, PhD, RN |
✓
|
163 |
| 3 |
3.2.4 |
Endothelial Dysfunction, Diminished Availability of cEPCs, Increasing CVD Risk for Macrovascular Disease – Therapeutic Potential of cEPCs |
https://pharmaceuticalintelligence.com/2012/08/27/endothelial-dysfunction-diminished-availability-of-cepcs-increasing-cvd-risk-for-macrovascular-disease-therapeutic-potential-of-cepcs/ |
Aviva Lev-Ari, PhD, RN |
✓
|
156 |
| 3 |
3.3.1 |
Clinical Trials Results for Endothelin System: Pathophysiological role in Chronic Heart Failure, Acute Coronary Syndromes and MI – Marker of Disease Severity or Genetic Determination? |
https://pharmaceuticalintelligence.com/2012/10/19/clinical-trials-results-for-endothelin-system-pathophysiological-role-in-chronic-heart-failure-acute-coronary-syndromes-and-mi-marker-of-disease-severity-or-genetic-determination/ |
Aviva Lev-Ari, PhD, RN |
✓
|
1749 |
| 3 |
3.4.1 |
Nitric Oxide and Sepsis, Hemodynamic Collapse, and the Search for Therapeutic Options |
https://pharmaceuticalintelligence.com/2012/10/20/nitric-oxide-and-sepsis-hemodynamic-collapse-and-the-search-for-therapeutic-options/ |
Larry Bernstein, MD, FACP |
✓
|
1173 |
| 3 |
3.4.2 |
Sepsis, Multi-organ Dysfunction Syndrome, and Septic Shock: A Conundrum of Signaling Pathways Cascading Out of Control |
https://pharmaceuticalintelligence.com/2012/10/13/sepsis-multi-organ-dysfunction-syndrome-and-septic-shock-a-conundrum-of-signaling-pathways-cascading-out-of-control/ |
Larry Bernstein, MD, FACP |
✓
|
1092 |
| 3 |
3.5.1 |
Nitric Oxide Function in Coagulation – Part II |
https://pharmaceuticalintelligence.com/2012/11/26/nitric-oxide-function-in-coagulation/ |
Larry Bernstein, MD, FACP |
✓
|
3426 |
| 4 |
4.1 |
Nitric Oxide Covalent Modifications: A Putative Therapeutic Target? |
https://pharmaceuticalintelligence.com/2012/09/24/nitric-oxide-covalent-modifications-a-putative-therapeutic-target/ |
Stephen J. Williams, PhD |
✓
|
360 |
| 5 |
5.1 |
Nitric Oxide in bone metabolism |
https://pharmaceuticalintelligence.com/2012/07/16/nitric-oxide-in-bone-metabolism/ |
Aviral Vatsa PhD, MBBS |
✓
|
359 |
| 6 |
6.1 |
Nitric Oxide and Immune Responses: Part 1 |
https://pharmaceuticalintelligence.com/2012/10/18/nitric-oxide-and-immune-responses-part-1/ |
Aviral Vatsa PhD, MBBS |
✓
|
908 |
| 6 |
6.2 |
Nitric Oxide and Immune Responses: Part 2 |
https://pharmaceuticalintelligence.com/2012/10/28/nitric-oxide-and-immune-responses-part-2/ |
Aviral Vatsa PhD, MBBS |
✓
|
3426 |
| 6 |
6.3 |
Nitric Oxide production in Systemic sclerosis |
https://pharmaceuticalintelligence.com/2012/07/25/nitric-oxide-production-in-systemic-sclerosis/ |
Aviral Vatsa PhD, MBBS |
✓
|
108 |
| 7 |
7.1 |
‘Lung-on-a-chip’ |
https://pharmaceuticalintelligence.com/2012/11/29/lung-on-a-chip/ |
Ritu Saxena, Ph.D. |
✓
|
387 |
| 7 |
7.2 |
Low Bioavailability of Nitric Oxide due to Misbalance in Cell Free Hemoglobin in Sickle Cell Disease – A Computational Model |
https://pharmaceuticalintelligence.com/2012/11/09/low-bioavailability-of-nitric-oxide-due-to-misbalance-in-cell-free-hemoglobin-in-sickle-cell-disease-a-computational-model/ |
Anamika Sarkar, Ph.D. |
✓
|
1145 |
| 7 |
7.3 |
The rationale and use of inhaled NO in Pulmonary Artery Hypertension and Right Sided Heart Failure |
https://pharmaceuticalintelligence.com/2012/08/20/the-rationale-and-use-of-inhaled-no-in-pulmonary-artery-hypertension-and-right-sided-heart-failure/ |
Larry Bernstein, MD, FACP |
✓
|
333 |
| 7 |
7.4 |
Transposon-mediated Gene Therapy improves Pulmonary Hemodynamics and attenuates Right Ventricular Hypertrophy: eNOS gene therapy reduces Pulmonary vascular remodeling and Arterial wall hyperplasia |
https://pharmaceuticalintelligence.com/2013/05/31/transposon-mediated-gene-therapy-improves-pulmonary-hemodynamics-and-attenuates-right-ventricular-hypertrophy-enos-gene-therapy-reduces-pulmonary-vascular-remodeling-and-arterial-wall-hyperplasia/ |
Aviva Lev-Ari, PhD, RN |
✓
|
50 |
| 8 |
8.1 |
The Amazing Structure and Adaptive Functioning of the Kidneys: Nitric Oxide – Part I |
https://pharmaceuticalintelligence.com/2012/11/26/the-amazing-structure-and-adaptive-functioning-of-the-kidneys/ |
Larry Bernstein, MD, FACP |
✓
|
991 |
| 8 |
8.2 |
Nitric Oxide and iNOS have Key Roles in Kidney Diseases – Part II |
https://pharmaceuticalintelligence.com/2012/11/26/nitric-oxide-and-inos-have-key-roles-in-kidney-diseases/ |
Larry Bernstein, MD, FACP |
✓
|
589 |
| 8 |
8.3 |
The Molecular Biology of Renal Disorders: Nitric Oxide – Part III |
https://pharmaceuticalintelligence.com/2012/11/26/the-molecular-biology-of-renal-disorders/ |
Larry Bernstein, MD, FACP |
✓
|
161 |
| 8 |
8.4 |
New Insights on Nitric Oxide donors – Part IV |
https://pharmaceuticalintelligence.com/2012/11/26/new-insights-on-no-donors/ |
Larry Bernstein, MD, FACP |
✓
|
289 |
| 8 |
8.5 |
The Essential Role of Nitric Oxide and Therapeutic NO Donor Targets in Renal Pharmacotherapy |
https://pharmaceuticalintelligence.com/2012/11/26/the-essential-role-of-nitric-oxide-and-therapeutic-no-donor-targets-in-renal-pharmacotherapy/ |
Larry Bernstein, MD, FACP |
✓
|
514 |
| 9 |
9.1 |
Crucial role of Nitric Oxide in Cancer |
https://pharmaceuticalintelligence.com/2012/10/16/crucial-role-of-nitric-oxide-in-cancer/ |
Ritu Saxena, Ph.D. |
✓
|
1393 |
2012pharmaceutical
sjwilliamspa